ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
티쎈트릭(아테졸리주맙) 시장 규모는 향후 몇 년간 급속한 성장을 기록할 것으로 예상됩니다. 예측 기간 동안의 성장은 조기 진단 및 예방에 대한 관심 증가, 암 생존율 향상, 글로벌 암 연구 프로젝트 확대, 개발도상국의 의료비 지출 증가, 환자 및 의료진들의 인식 개선 등에 기인합니다. 예측 기간 동안 주요 트렌드로는 인공지능(AI) 통합, 원격 의료 및 원격 모니터링, 규제 혁신, 바이오마커 발견의 진전, 혁신적인 신약 개발 등이 포함됩니다.
암의 유병률 증가가 티쎈트릭(아테졸리주맙) 시장 성장을 촉진할 것으로 예상됩니다. 이 암 사례 증가의 원인은 고령화 인구, 진단 기술의 개선, 생활 방식 변화, 환경 노출, 생존율 향상 등이 있으며, 이 모든 요인이 더 많은 사람들이 암 진단을 받고 암과 함께 살아가는 데 기여하고 있습니다. 티쏀트릭(아테졸리주맙)은 암 치료에 필수적입니다. 이는 PD-L1이라는 단백질을 차단하여 암 세포가 면역 체계의 감지를 회피하는 것을 방지함으로써 면역 체계를 활용해 암과 싸웁니다. 이로써 면역 체계의 T세포가 암 세포를 더 효과적으로 인식하고 파괴할 수 있게 됩니다. 예를 들어, 2024년 1월 미국 암 협회는 암 환자 수가 2023년의 195만 8,310명에서 200만 1,140명으로 증가해 2.19%의 성장률을 기록했다고 보고했습니다. 이로 인해 암의 유병률 증가가 티쎈트릭(아테졸리주맙) 시장 성장을 촉진하고 있습니다.
티쎈트릭(아테졸리주맙) 장의 주요 트렌드는 정밀한 투여량, 빠른 전신 흡수, 일관된 치료 수준을 보장하기 위한 혁신적인 제품 개발입니다. 예를 들어, 아테졸리주맙의 정맥 주사 제형이 이에 해당됩니다. 정맥주사 제형은 정맥 내 주입을 통해 혈류에 직접 투여되는 액체 제제로, 전신 암 치료를 위해 단일클론 항체를 효율적으로 전달하도록 설계되었습니다. 예를 들어, 2024년 9월 Genentech Inc.는 미국 식품의약국(FDA)으로부터 아테졸리주맙과 히알루로니다제-TQJS의 피하 주사 제형에 대한 승인을 받았습니다. 미국에서 최초로 승인된 피하 투여용 항-PD-L1 치료제인 티쎈트릭은 정맥 내 투여에 필요한 30-60분 대비 약 7분의 빠른 투여 시간을 제공하며, IMscin001 임상 시험에서 약물 노출량과 전체 반응률 측면에서 유사한 효능을 유지합니다. 이 약물은 비소세포폐암(NSCLC), 소세포폐암(SCLC), 흑색종, 간세포암, 폐포 연부 조직 육종 등 다양한 성인 암에 대해 승인되었습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 바이오의약품 시장에서의 제품 특성
분자 유형
투여경로(ROA)
작용기전(MOA)
안전성과 유효성
제4장 시장 동향과 전략
제5장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염, 경기 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제6장 세계의 성장 분석과 전략 분석 프레임워크
세계의 티쎈트릭(아테졸리주맙) : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 티쎈트릭(아테졸리주맙) 시장 : 성장률 분석
세계의 티쎈트릭(아테졸리주맙) 시장 실적 : 규모와 성장(2019-2024년)
세계의 티쎈트릭(아테졸리주맙) 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 티쎈트릭(아테졸리주맙) : 전체 시장 규모(TAM)
제7장 세계 시장의 가격 분석과 예측
제8장 시장 세분화
세계의 티쎈트릭(아테졸리주맙) 시장 : 약제 클래스별, 분석과 예측(2019-2024년, 2024-2029년, 2043년)
PD-L1 억제제
PD-1 억제제
CTLA-4 억제제
면역 조절제
기타
세계의 티쎈트릭(아테졸리주맙) 시장 : 질환별, 분석과 예측(2019-2024년, 2024-2029년, 2043년)
폐암
방광암
흑색종
호지킨 림프종
두경부암
기타
세계의 티쎈트릭(아테졸리주맙) 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2043년)
병원 약국
소매 약국
온라인 약국
세계의 티쎈트릭(아테졸리주맙) 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2043년)
병원
재택 치료
전문 클리닉
기타
제9장 임상적응증 세계 시장 역학
약제의 부작용
임상적응증의 발병률과 유병률
제10장 지역별, 국가별 분석
세계의 티쎈트릭(아테졸리주맙) 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2043년)
세계의 티쎈트릭(아테졸리주맙) 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2043년)
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 한국 시장
제17장 서유럽 시장
제18장 영국 시장
제19장 독일 시장
제20장 프랑스 시장
제21장 동유럽 시장
제22장 북미 시장
제23장 미국 시장
제24장 캐나다 시장
제25장 남미 시장
제26장 중동 시장
제27장 아프리카 시장
제28장 경쟁 구도와 기업 프로파일
티쎈트릭(아테졸리주맙) 시장 : 경쟁 구도
티쎈트릭(아테졸리주맙) 시장 : 기업 프로파일
Roche Holding AG
Chugai Pharmaceutical Co. Ltd.
제29장 세계 시장 : 파이프라인 분석
제30장 세계 시장 경쟁 벤치마킹과 대시보드
제31장 주요 인수합병(M&A)
제32장 최근 시장 동향
제33장 시장의 잠재력이 높은 국가, 전략
티쎈트릭(아테졸리주맙) 시장(2029년) : 새로운 기회를 제공하는 국가
티쎈트릭(아테졸리주맙) 시장(2029년) : 새로운 기회를 제공하는 부문
티쎈트릭(아테졸리주맙) 시장(2029년) : 성장 전략
시장 동향에 의한 전략
경쟁 전략
제34장 부록
HBR
영문 목차
영문목차
Tecentriq (atezolizumab) is a monoclonal antibody-based immunotherapy that belongs to a class of cancer treatments called immune checkpoint inhibitors. It specifically targets the protein programmed death ligand 1 (PD-L1), blocking the interaction between PD-L1 (found on tumor and immune cells) and PD-1 or B7.1 receptors on T-cells. This inhibition reactivates the immune system, allowing T-cells to recognize and destroy cancer cells.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary types of tecentriq (atezolizumab) include PD-L1 inhibitors, PD-1 inhibitors, CTLA-4 inhibitors, immunomodulators, and others. Tecentriq PD-L1 Inhibitor is a monoclonal antibody that blocks PD-L1, a protein that suppresses the immune response against cancer cells. It is used for treating lung cancer, bladder cancer, melanoma, Hodgkin's lymphoma, head and neck cancer, and others. Tecentriq is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and is used by different end users such as hospitals, home care providers, specialty clinics, and others.
The tecentriq (atezolizumab) market research report is one of a series of new reports from The Business Research Company that provides tecentriq (atezolizumab) market statistics, including tecentriq (atezolizumab) industry global market size, regional shares, competitors with a tecentriq (atezolizumab) market share, detailed tecentriq (atezolizumab) market segments, market trends and opportunities, and any further data you may need to thrive in the tecentriq (atezolizumab) industry. This tecentriq (atezolizumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The tecentriq (atezolizumab) market size is expected to see rapid growth in the next few years. It will grow to $6,850 million in 2029 at a compound annual growth rate (CAGR) of 12%. The growth in the forecast period can be attributed to increasing focus on early detection and prevention, growing cancer survival rates, expanding global cancer research initiatives, higher healthcare spending in developing economies, growing awareness among patients and physicians. Major trends in the forecast period include integration of artificial intelligence (AI), telemedicine and remote monitoring, regulatory Innovations, advancements in biomarker discovery, innovative drug development.
The increasing prevalence of cancer is expected to drive the growth of the tecentriq (atezolizumab) market. This rise in cancer cases can be attributed to factors such as an aging population, better detection techniques, lifestyle changes, environmental exposures, and improved survival rates, all contributing to more people being diagnosed and living with cancer. Tecentriq (atezolizumab) is vital for cancer treatment as it utilizes the immune system to combat cancer by blocking PD-L1, a protein that allows tumors to evade immune detection. This enables the immune system's T-cells to recognize and destroy cancer cells more effectively. For example, in January 2024, the American Cancer Society reported a rise in cancer cases, with the number of new cases increasing to 2,001,140 from 1,958,310 in 2023, a growth of 2.19%. As a result, the growing prevalence of cancer is driving the tecentriq (atezolizumab) market forward.
A key trend in the tecentriq (atezolizumab) market is the development of innovative products, such as intravenous formulations of atezolizumab, aimed at ensuring precise dosing, rapid systemic absorption, and consistent therapeutic levels. The intravenous formulation is a liquid preparation administered directly into the bloodstream via infusion, designed to efficiently deliver the monoclonal antibody for systemic cancer treatment. For example, in September 2024, Genentech Inc. received approval from the U.S. Food and Drug Administration for atezolizumab and hyaluronidase-tqjs for subcutaneous injection. Tecentriq, the first subcutaneous anti-PD-L1 therapy approved in the U.S., offers a distinct advantage with a faster administration time of approximately 7 minutes compared to the 30-60 minutes required for intravenous infusion, while maintaining comparable efficacy in drug exposure and overall response rates, as demonstrated in the IMscin001 trial. It is approved for various adult cancers, including NSCLC, SCLC, melanoma, hepatocellular carcinoma, and alveolar soft part sarcoma.
In October 2024, Lonza Group AG, a Switzerland-based pharmaceutical, biotechnology, and nutrition company, acquired Roche's Vacaville large-scale biologics manufacturing facility for $1.2 billion. This acquisition establishes a strong West Coast manufacturing presence near the San Francisco biotech hub, complementing Lonza's existing East Coast site in Portsmouth, New Hampshire, and its global network in Europe and Asia Pacific. The expansion significantly strengthens Lonza's ability to manufacture late-stage clinical and commercial products and support the production of new molecules approaching commercialization. Roche Holding AG, a Switzerland-based manufacturer of pharmaceuticals and biologics, produces Tecentriq (atezolizumab).
Major players operating in the tecentriq (atezolizumab) market are Roche Holding AG, and Chugai Pharmaceutical Co. Ltd.
North America was the largest region in the tecentriq (atezolizumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in tecentriq (atezolizumab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the tecentriq (atezolizumab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The tecentriq (atezolizumab) market consists of sales of biosimilars, immuno-oncology pipeline drugs, supportive oncology medications and related products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Tecentriq (Atezolizumab) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on tecentriq (atezolizumab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for tecentriq (atezolizumab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The tecentriq (atezolizumab) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Drug Class: PD-L1 Inhibitors; PD-1 Inhibitors; CTLA-4 Inhibitors; Immunomodulators; Other Drug Classes
2) By Clinical Indication: Lung Cancer; Bladder Cancer; Melanoma; Hodgkin's Lymphoma; Head And Neck Cancer; Other Indications
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
4) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
3. Tecentriq (Atezolizumab) Market Biologic Drug Characteristics
3.1. Molecule Type
3.2. Route Of Administration (ROA)
3.3. Mechanism Of Action (MOA)
3.4. Safety And Efficacy
4. Tecentriq (Atezolizumab) Market Trends And Strategies
5. Tecentriq (Atezolizumab) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market
6. Global Tecentriq (Atezolizumab) Growth Analysis And Strategic Analysis Framework
6.1. Global Tecentriq (Atezolizumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
6.2. Analysis Of End Use Industries
6.3. Global Tecentriq (Atezolizumab) Market Growth Rate Analysis
6.4. Global Tecentriq (Atezolizumab) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
6.5. Global Tecentriq (Atezolizumab) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
6.6. Global Tecentriq (Atezolizumab) Total Addressable Market (TAM)
7. Global Tecentriq (Atezolizumab) Market Pricing Analysis & Forecasts
8. Tecentriq (Atezolizumab) Market Segmentation
8.1. Global Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
PD-L1 Inhibitors
PD-1 Inhibitors
CTLA-4 Inhibitors
Immunomodulators
Other Drug Classes
8.2. Global Tecentriq (Atezolizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Lung Cancer
Bladder Cancer
Melanoma
Hodgkin's Lymphoma
Head And Neck Cancer
Other Indications
8.3. Global Tecentriq (Atezolizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
8.4. Global Tecentriq (Atezolizumab) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Homecare
Specialty Clinics
Other End Users
9. Global Tecentriq (Atezolizumab) Market Epidemiology Of Clinical Indications
9.1. Drug Side Effects
9.2. Incidence And Prevalence of Clinical Indications
10. Tecentriq (Atezolizumab) Market Regional And Country Analysis
10.1. Global Tecentriq (Atezolizumab) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. Global Tecentriq (Atezolizumab) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Asia-Pacific Tecentriq (Atezolizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Asia-Pacific Tecentriq (Atezolizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. China Tecentriq (Atezolizumab) Market
12.1. China Tecentriq (Atezolizumab) Market Overview
12.2. China Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
12.3. China Tecentriq (Atezolizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
12.4. China Tecentriq (Atezolizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
13. India Tecentriq (Atezolizumab) Market
13.1. India Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. India Tecentriq (Atezolizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. India Tecentriq (Atezolizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. Japan Tecentriq (Atezolizumab) Market
14.1. Japan Tecentriq (Atezolizumab) Market Overview
14.2. Japan Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. Japan Tecentriq (Atezolizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. Japan Tecentriq (Atezolizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Australia Tecentriq (Atezolizumab) Market
15.1. Australia Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.2. Australia Tecentriq (Atezolizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Australia Tecentriq (Atezolizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. South Korea Tecentriq (Atezolizumab) Market
16.1. South Korea Tecentriq (Atezolizumab) Market Overview
16.2. South Korea Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. South Korea Tecentriq (Atezolizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.4. South Korea Tecentriq (Atezolizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Western Europe Tecentriq (Atezolizumab) Market
17.1. Western Europe Tecentriq (Atezolizumab) Market Overview
17.2. Western Europe Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Western Europe Tecentriq (Atezolizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.4. Western Europe Tecentriq (Atezolizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. UK Tecentriq (Atezolizumab) Market
18.1. UK Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. UK Tecentriq (Atezolizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. UK Tecentriq (Atezolizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Germany Tecentriq (Atezolizumab) Market
19.1. Germany Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Germany Tecentriq (Atezolizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Germany Tecentriq (Atezolizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. France Tecentriq (Atezolizumab) Market
20.1. France Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. France Tecentriq (Atezolizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. France Tecentriq (Atezolizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Tecentriq (Atezolizumab) Market
21.1. Eastern Europe Tecentriq (Atezolizumab) Market Overview
21.2. Eastern Europe Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Tecentriq (Atezolizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Tecentriq (Atezolizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. North America Tecentriq (Atezolizumab) Market
22.1. North America Tecentriq (Atezolizumab) Market Overview
22.2. North America Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. North America Tecentriq (Atezolizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.4. North America Tecentriq (Atezolizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. USA Tecentriq (Atezolizumab) Market
23.1. USA Tecentriq (Atezolizumab) Market Overview
23.2. USA Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. USA Tecentriq (Atezolizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. USA Tecentriq (Atezolizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.2. Canada Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. Canada Tecentriq (Atezolizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. Canada Tecentriq (Atezolizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. South America Tecentriq (Atezolizumab) Market
25.1. South America Tecentriq (Atezolizumab) Market Overview
25.2. South America Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. South America Tecentriq (Atezolizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. South America Tecentriq (Atezolizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. Middle East Tecentriq (Atezolizumab) Market
26.1. Middle East Tecentriq (Atezolizumab) Market Overview
26.2. Middle East Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. Middle East Tecentriq (Atezolizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. Middle East Tecentriq (Atezolizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Africa Tecentriq (Atezolizumab) Market
27.1. Africa Tecentriq (Atezolizumab) Market Overview
27.2. Africa Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Africa Tecentriq (Atezolizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.4. Africa Tecentriq (Atezolizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Tecentriq (Atezolizumab) Market Competitive Landscape And Company Profiles
